BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HSK39004 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of HSK39004\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07658339-1539@assetmemo.bio
DTSTAMP:20261121T005718Z
DTSTART;VALUE=DATE:20270611
DTEND;VALUE=DATE:20270612
SUMMARY:HSK39004: Phase 3 readout est. (NCT07658339)
DESCRIPTION:HSK39004\, phase 3\, Chronic Obstructive Pulmonary Disease.\nSt
 udy: A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of HSK39
 004 Inhalation Suspension in Patients With COPD\nEstimated primary complet
 ion: 11 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hs
 k39004#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07658339
URL:https://assetmemo.bio/drug/hsk39004#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07425210-1539@assetmemo.bio
DTSTAMP:20261121T005718Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:HSK39004: Phase 2 readout est. (NCT07425210)
DESCRIPTION:HSK39004\, phase 2\, Chronic Obstructive Pulmonary Disease.\nSt
 udy: Long-Term Safety and Efficacy of HSK39004 Dry Powder Inhaler in COPD\
 nEstimated primary completion: July 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/hsk39004#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07425210
URL:https://assetmemo.bio/drug/hsk39004#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07583849-1539@assetmemo.bio
DTSTAMP:20261121T005718Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:HSK39004: Phase 3 readout est. (NCT07583849)
DESCRIPTION:HSK39004\, phase 3\, Chronic Obstructive Pulmonary Disease.\nSt
 udy: A Multicenter\, Randomized\, Double-blind\, Placebo-controlled\, Para
 llel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment
  of COPD\nEstimated primary completion: 30 September 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/hsk39004#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07583849
URL:https://assetmemo.bio/drug/hsk39004#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07634367-1539@assetmemo.bio
DTSTAMP:20261121T005718Z
DTSTART;VALUE=DATE:20271224
DTEND;VALUE=DATE:20271225
SUMMARY:HSK39004: Phase 3 readout est. (NCT07634367)
DESCRIPTION:HSK39004\, phase 3\, Chronic Obstructive Pulmonary Disease.\nSt
 udy: Long-Term Safety and Efficacy of HSK39004 Inhalation Suspension in CO
 PD\nEstimated primary completion: 24 December 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/hsk39004#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07634367
URL:https://assetmemo.bio/drug/hsk39004#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
